Voya Investment Management LLC Makes New Investment in InfuSystem Holdings, Inc. $INFU

Key Points

• Voya Investment Management LLC has acquired 33,890 shares of InfuSystem Holdings, Inc., valued at approximately $182,000, representing a 0.16% stake in the company.
• A variety of institutional investors, including Acadian Asset Management and Cove Street Capital, have recently increased their stakes in InfuSystem, indicating growing interest in the company.
• Wall Street analysts have a positive outlook on InfuSystem, with an average rating of "Strong Buy" and a target price of $13.50 for the stock.

Voya Investment Management LLC acquired a new position in InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The fund acquired 33,890 shares of the company's stock, valued at approximately $182,000. Voya Investment Management LLC owned approximately 0.16% of InfuSystem at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC lifted its holdings in InfuSystem by 219.1% in the 1st quarter. Acadian Asset Management LLC now owns 39,117 shares of the company's stock worth $208,000 after buying an additional 26,860 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of InfuSystem in the 1st quarter worth about $96,000. Cove Street Capital LLC increased its position in shares of InfuSystem by 8.7% in the 1st quarter. Cove Street Capital LLC now owns 210,301 shares of the company's stock worth $1,131,000 after purchasing an additional 16,851 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of InfuSystem in the 1st quarter worth about $129,000. Finally, Jump Financial LLC bought a new stake in shares of InfuSystem in the 1st quarter worth about $58,000. Institutional investors and hedge funds own 71.13% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on INFU shares. Lake Street Capital started coverage on shares of InfuSystem in a research report on Monday, September 22nd. They issued a "buy" rating and a $15.00 target price for the company. Roth Capital started coverage on shares of InfuSystem in a research report on Tuesday, July 22nd. They issued a "buy" rating and a $12.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Strong Buy" and an average target price of $13.50.

Insider Transactions at InfuSystem

In other InfuSystem news, Director Scott Shuda sold 5,752 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $9.67, for a total transaction of $55,621.84. Following the completion of the transaction, the director directly owned 94,000 shares of the company's stock, valued at $908,980. The trade was a 5.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 11.40% of the stock is owned by insiders.

InfuSystem Trading Down 1.3%

InfuSystem stock opened at $10.36 on Wednesday. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average price of $9.08 and a two-hundred day moving average price of $6.81. The firm has a market capitalization of $211.61 million, a price-to-earnings ratio of 172.70 and a beta of 1.82. InfuSystem Holdings, Inc. has a 52-week low of $4.61 and a 52-week high of $11.04.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.